Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
Historique:
pubmed:
10
2
2021
medline:
19
3
2022
entrez:
9
2
2021
Statut:
ppublish
Résumé
The ANCHOR program offered buprenorphine treatment to people who inject drugs engaged in hepatitis C (HCV) treatment at a Washington, DC harm reduction organization. This analysis describes the program model and outcomes of the opioid care continuum at 1 year. Primary outcomes were initiation of buprenorphine and retention in care, defined by an active buprenorphine prescription at given time points. Secondary outcomes included treatment interruptions, reasons for treatment noninitiation and termination, buprenorphine and opiate use, and HIV risk behaviors. Buprenorphine and opiate use were measured by urine toxicology screens and HIV risk behavior was quantified using a validated survey. Of 67 patients receiving HCV treatment not on opioid agonist therapy at baseline, 96% (n = 64) were interested and 73% (n = 49) initiated buprenorphine. Retention was 82% (n = 40), 65% (n = 32), and 59% (n = 29) at months 1, 6, and 12, respectively. Retention at 12 months was associated with self-reported engagement in routine medical care (P < 0.01), but was not associated with gender, stable housing, past opioid agonist therapy, or past overdose. Among retained patients, urine screens positive for opioids were 73% (n = 29), 56% (n = 18), and 79% (n = 23) at months 1, 6, and 12. There was a significant mean decrease in HIV risk-taking behavior scores over the treatment period, primarily driven by reduced injection frequency. Patients engaged in HCV treatment at a harm reduction organization showed a high rate of initiation of buprenorphine treatment, with retention comparable to other treatment settings. Although most patients continued using opioids on treatment, there was a reduced frequency of injection drug use, a significant driver of OUD-related risk. These data support the use of low-threshold buprenorphine access alongside HCV treatment to reduce morbidity and mortality in people with OUD.
Identifiants
pubmed: 33560694
doi: 10.1097/ADM.0000000000000807
pii: 01271255-202202000-00007
pmc: PMC8923533
mid: NIHMS1669938
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-17Subventions
Organisme : CLC NIH HHS
ID : HHSN269201400012C
Pays : United States
Organisme : NHLBI NIH HHS
ID : K12 HL143886
Pays : United States
Informations de copyright
Copyright © 2021 American Society of Addiction Medicine.
Références
Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths — United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2019; 67:1419–1427.
Ahmad FB, Escobedo LA, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts National Center for Health Statistics 2019.
Wu TL, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend 2016; 1 (169):117–127.
Williams R, Nunes E, Olfson M. To battle the opioid overdose epidemic, deploy the “cascade of care” model. Health Affairs Blog. Available at: https://www.healthaffairs.org/do/10.1377/hblog20170313.059163/full/ . Accessed May 7, 2020.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2019. Retrieved from https://www.samhsa.gov/data/ . Accessed May 7, 2020.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; Issue 2. Art. No.: CD002207. DOI: 10.1002/14651858.CD002207.pub4.
doi: 10.1002/14651858.CD002207.pub4
Ma J, Wang R, Su M, et al. Effects of opiate substitution treatment on mortality for opioids users: A systematic review and meta-analysis. Lancet 2017; 390: doi:10.1016/s0140-6736(17)33194-x.
doi: 10.1016/s0140-6736(17)33194-x
Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med 2018; 169:137–145.
Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017; 357:1–14.
Korthuis PT, Mccarty D, Weimer M, et al. Primary care–based models for the treatment of opioid use disorder: A scoping review. Ann Intern Med 2016; 166 (4):268–278.
Carrieri PM, Michel L, Lions C, et al. Methadone induction in primary care for opioid dependence: A pragmatic randomized trial (ANRS Methaville). PLoS One 2014; 9 (11):1–10.
Wittchen HU, Apelt SM, Soyka M, et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients. Drug Alcohol Depend 2008; 95 (3):245–257.
Fox AD, Chamberlain A, Sohler NL, et al. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. J Subst Abuse Treat 2015; 48 (1):112–116.
French MT, Mcgeary KA, Chitwood DD, Mccoy CB. Chronic illicit drug use, health services utilization and the cost of medical care. Soc Sci Med 2000; 50 (12):1703–1713.
Mcknight C, Shumway M, Masson CL, et al. Perceived discrimination among racial and ethnic minority drug users and the association with health care utilization. J Ethn Subst Abuse 2017; 16 (4):404–419.
Neale J, Tompkins C, Sheard L. Barriers to accessing generic health and social care services: A qualitative study of injecting drug users. Health Soc Care Community 2007; 16 (2):147–154.
Cisneros GO, Douaihy AB, Kirisci L. Access to healthcare among injection drug users at a needle exchange program in Pittsburgh, PA. J Addict Med 2009; 3 (2):89–94.
Bazazi AR, Yokell M, Fu JJ, et al. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med 2011; 5 (3):175–180.
Fox AD, Chamberlain A, Frost T, Cunningham CO. Harm reduction agencies as a potential site for buprenorphine treatment. Subst Abuse 2015; 36 (2):155–160.
Perreault M, Héroux MC, White ND, Lauzon P, Mercier C, Rousseau M. Rétention en traitement et évolution de la clientèle d’un programme montréalais de substitution à la méthadone à exigences peu élevees [Treatment retention and evolution of clientele in a low threshold methadone substitution treatment program in Montreal]. Can J Public Health 2007; 98 (1):33–36.
Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health 2001; 91 (5):774–780.
Millson P, Challacombe L, Villeneuve PL, et al. Reduction in injection-related HIV risk after 6 months in a low-threshold methadone treatment program. AIDS Educ Prev 2007; 19 (2):124–136.
Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abus 2018; 39:167–172.
Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis 2012; 31 (3):278–287.
Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. J Subst Abuse Treat 2019; 103:1–8.
Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract 2019; 14 (1):1–9.
Rosenthal ES, Silk R, Mathur P, et al. Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs. Clin Infect Dis 2020; 71:1715–1722.
Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders. Fifth edArlington, VA: American Psychiatric Association; 2013.
US Food and Drug Administration. FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. 2017. Washington, DC.
Darke S, Hall W, Heather N, Ward J, Wodak A. The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. AIDS 1991; 5 (2):181–185.
Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Glob Health 2017; 5 (12):e1192–e1207. Erratum in: Lancet Glob Health. 2017 Nov 15: PMID: 29074409; PMCID: PMC5683738.
Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40: (suppl 5): S313–S320.
Caven M, Malaguti A, Robinson E, Fletcher E, Dillon JF. Impact of hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review. Int J Drug Policy 2019; 72:169–176.
Nacht J. Emergency department-initiated buprenorphine/nalaxone treatment for opioid dependence: A randomized clinical trial. J Emerg Med 2015; 49 (5):831–832.
Liebschutz J, Crooks D, Herman D, et al. Initiating buprenorphine maintenance for opiate-dependent hospitalized patients: A randomized controlled trial. J Gen Intern Med 2013; 28:S108–S109.
Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes. Drug Alcohol Depend 2013; 131 (1–2):127–135.
Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience. Arch Intern Med 2011; 171 (5):425–431.
Hersh D, Little SL, Gleghorn A. Integrating buprenorphine treatment into a public healthcare system: The San Francisco Department of Public Health's office-based buprenorphine pilot program. J Psychoactive Drugs 2011; 43 (2):136–145.
Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services.
Wilson LE, Thomas DL, Astemborski J, Freedman TL, Vlahov D. Prospective study of infective endocarditis among injection drug users. J Infect Dis 2002; 185 (12):1761–1766.
Moradi-Joo M, Ghiasvand H, Noroozi M, et al. Prevalence of skin and soft tissue infections and its related high-risk behaviors among people who inject drugs: A systematic review and meta-analysis. J Subst Use 2019; 24:350–360. 4.
U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. (2018). Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment, Guidance for Industry. Retrieved from https://www.fda.gov/files/drugs/published/Opioid-Use-Disorder---Endpoints-for-Demonstrating-Effectiveness-of-Drugs-for-Medication-Assisted-Treatment--Guidance-for-Industry.pdf . Accessed May 7, 2020.